Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MEDI1191 |
Synonyms | |
Therapy Description |
MEDI1191 is an encapsulated mRNA formulation of interleukin-12 subunit beta (IL12B) and interleukin-12 subunit alpha (IL12A), which activate the immune system and prevent tumor cell proliferation (PMID: 32817076). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MEDI1191 | MEDI-1191|MEDI 1191 | MEDI1191 is an encapsulated mRNA formulation of interleukin-12 subunit beta (IL12B) and interleukin-12 subunit alpha (IL12A), which activate the immune system and prevent tumor cell proliferation (PMID: 32817076). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03946800 | Phase I | MEDI1191 Durvalumab + MEDI1191 | A Study of MEDI1191 Alone and in Combination With Durvalumab in Subjects With Advanced Solid Tumors | Completed | USA | ESP | 0 |